IDEAYA reports positive Phase 1 data for IDE849 in SCLC, positive Phase 2 darovasertib in UM, positive IDE397 combo data

IDEAYA Biosciences, Inc.

IDE849 (DLL3 ADC) showed 73.2% ORR (52/71) and 47.9% confirmed ORR in SCLC at >=2.4 mg/kg; median PFS 6.7 months.
Darovasertib neoadjuvant UM trial: 76% (16/21) achieved >=20% tumor shrinkage; 48% had >=20% reduction in simulated radiation dose.
IDE397 (MAT2A) + Trodelvy in MTAP-del UC: 33% ORR at DL1 (3cPR), 57% ORR at DL2 (3cPR+1uPR); DCR up to 100%.
Phase 3 OptimUM-10 trial for darovasertib in neoadjuvant primary UM initiated Q2 2025; additional data at ESMO Oct 2025.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.